Literature DB >> 1716712

Significance of anti-phospholipid antibodies in patients with lupus nephritis.

G Frampton1, J Hicks, J S Cameron.   

Abstract

Anti-phospholipid antibodies (APA) as markers or mediators of thrombosis in lupus could be of pathogenetic significance in nephritis, since glomerular capillary thrombi are an indicator of subsequent renal dysfunction. Isotype specific APA antibodies were measured, using cardiolipin as the antigen, in 76 patients with lupus nephritis. Twenty-nine percent of the patients had elevated IgG APA. Overall, 43% of patients showed raised levels of at least one isotype. In general, APA had specificity for anionic phospholipids. In vitro lupus anticoagulant activity was associated with all three isotypes of APA, but only the IgM isotype correlated with the biological false positive test for syphilis. APA were not associated with thromboses or neurological involvement, and only the IgA isotype correlated with thrombocytopenia. We confirmed an association between the presence of intraglomerular thrombi and serum IgG APA. However, we found no association between APA and renal histological pattern, or long-term renal function. Our data, therefore, do not support a major pathogenetic role for APA in the nephritis of lupus in treated patients.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1716712     DOI: 10.1038/ki.1991.155

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  19 in total

Review 1.  Renal involvement in antiphospholipid syndrome.

Authors:  Francisco Vileimar Andrade de Azevedo; Diego Germano Maia; Jozelio Freire de Carvalho; Carlos Ewerton Maia Rodrigues
Journal:  Rheumatol Int       Date:  2018-05-05       Impact factor: 2.631

2.  Anti-beta2GPI-antibody-induced endothelial cell gene expression profiling reveals induction of novel pro-inflammatory genes potentially involved in primary antiphospholipid syndrome.

Authors:  C Hamid; K Norgate; D P D'Cruz; M A Khamashta; M Arno; J D Pearson; G Frampton; J J Murphy
Journal:  Ann Rheum Dis       Date:  2007-01-12       Impact factor: 19.103

Review 3.  Treatment of lupus nephritis.

Authors:  Fayez F Hejaili; Louise M Moist; William F Clark
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 4.  Use of eculizumab in a systemic lupus erythemathosus patient presenting thrombotic microangiopathy and heterozygous deletion in CFHR1-CFHR3. A case report and systematic review.

Authors:  Maria Izabel de Holanda; Luis Cristóvão Pôrto; Teresa Wagner; Luis Fernando Christiani; Lilian M P Palma
Journal:  Clin Rheumatol       Date:  2017-09-13       Impact factor: 2.980

Review 5.  Antiphospholipid syndrome and vascular ischemic (occlusive) diseases: an overview.

Authors:  Penka A Atanassova
Journal:  Yonsei Med J       Date:  2007-12-31       Impact factor: 2.759

Review 6.  Renal involvement in the antiphospholipid syndrome (APS)-APS nephropathy.

Authors:  Maria G Tektonidou
Journal:  Clin Rev Allergy Immunol       Date:  2009-06       Impact factor: 8.667

Review 7.  Thrombotic microangiopathic haemolytic anaemia and antiphospholipid antibodies.

Authors:  G Espinosa; S Bucciarelli; R Cervera; M Lozano; J-C Reverter; G de la Red; V Gil; M Ingelmo; J Font; R A Asherson
Journal:  Ann Rheum Dis       Date:  2004-06       Impact factor: 19.103

8.  Lupus nephritis and Raynaud's phenomenon are significant risk factors for vascular thrombosis in SLE patients with positive antiphospholipid antibodies.

Authors:  Kittiwan Choojitarom; Orawan Verasertniyom; Kitti Totemchokchyakarn; Kanokrat Nantiruj; Vasant Sumethkul; Suchela Janwityanujit
Journal:  Clin Rheumatol       Date:  2007-09-02       Impact factor: 2.980

9.  Significance of anti-entactin antibodies in patients with systemic lupus erythematosus and related disorders.

Authors:  R Saxena; G Sturfelt; O Nived; J Wieslander
Journal:  Ann Rheum Dis       Date:  1994-10       Impact factor: 19.103

10.  Antiphospholipid antibody profiles in lupus nephritis with glomerular microthrombosis: a prospective study of 124 cases.

Authors:  Hui Zheng; Yi Chen; Wen Ao; Yan Shen; Xiao-wei Chen; Min Dai; Xiao-dong Wang; Yu-cheng Yan; Cheng-de Yang
Journal:  Arthritis Res Ther       Date:  2009-06-22       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.